Effect of Baseline Resistance-Associated Substitutions on Thalassemia Patients with Chronic HCV Infection: A Two-Year Follow-Up

Fahimeh Safarnezhad Tameshkel 1, Mohammad Hadi Karbalaie Niya 1,2, Mahmoodreza Khoonsari 1, Hossein Ajdarkosh 1, Amir Hossein Faraji 1, Mehdi Nikkhah 1, Nima Motamed 3, Azita Azarkeivan 4, Ali Gholami 5,6, Masood Reza Sohrabi 1, Hossein Keyvani 1,2, Farhad Zamani 1,*

1. Gastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, Iran
2. Department of Virology, Iran University of Medical Sciences, Tehran, Iran
3. Department of Social Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
4. Pediatric Hematology Oncology, Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Thalassemia Clinic, Tehran, Iran
5. Non-communicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran
6. Department of Epidemiology & Biostatistics, School of Public Health, Neyshabur University of Medical Sciences, Neyshabur, Iran

* Corresponding Author:
Farhad Zamani, MD
Gastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, Iran
Tel: + 98 21 88941831
Fax: + 98 21 88941831
Email: zamani.f@iums.ac.ir

ABSTRACT

BACKGROUND

Direct-acting antivirals (DAAs) against hepatitis C virus (HCV) infection showed the presence of resistant-associated substitutions (RASs). The aim of the present study was to carry out a follow-up of patients with baseline RASs to report the impact of RASs on DAA therapy outcome.

METHODS

In a cohort study, we analyzed NS5A and NS5B RASs among nine thalassemia cases by baseline RASs. In a 2-year follow-up, we analyzed viral markers and biochemical and hematological parameters of the participants and their sustained virologic response (SVR). Statistical analyses were performed using SPSS software version 22.

RESULTS

RASs for HCV subtype 1a included M28V, L31M, and H58P. For subtype 1b: L28M, R30Q, S24F, and C316N. And for subtype 3a: C316S, and S24F. In patients with cirrhosis (n = 5), ALT (p = 0.001) and AST (p = 0.007) levels were significantly reduced after treatment, and creatinine level slightly increased (p = 0.025). However, no significant data was observed in non-cirrhotic patients following the treatment.

CONCLUSION

The present study did not show any adverse effects of DAA therapy among patients with thalassemia suffering from chronic HCV infection with baseline RASs. Furthermore, reduction in ferritin and liver stiffness levels after DAA therapy could show the efficacy of DAA in such patients.

KEYWORDS:

Direct acting antivirals (DAAs), Resistant associated substitutions (RASs), Chronic HCV infection

Received: 10 Jul. 2020
Accepted: 16 Dec. 2020

DOI: 10.34172/mejdd.2021.200

© 2021 The Author(s). This work is published by Middle East Journal of Digestive Diseaes as an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited.
INTRODUCTION

Globally, 71 million individuals suffer from chronic hepatitis C virus (HCV) infection with genotypes having specific geographical differences.\(^1\) HCV lifecycle is associated with intra- and extrahepatocellular complications, such as cirrhosis and hepatocellular carcinoma (HCC).\(^2\) However, recently, it has been shown that direct-acting antivirals (DAAs) have extensively been effective and can reduce the disease burden. It has been shown that DAAs results in a sustained virologic response (SVR) in more than 90% of the treated patients.\(^3\)

Recently, wide range usage of DAAs against HCV has increased the risk of emerging resistant-associated variants (RAVs) and/or resistant associated substitutions (RASs). Although RASs usually lead to single or multiple antiviral drug resistance, their functions have been altered in unknown situations.\(^4,5\) Moreover, there is some evidence that elucidates the co-occurrence of RASs, such as C316N in 1b subtype NS5B gene, which has co-occurring mutations, including L159F, A207T, and A218S. This phenomenon could enhance antiviral resistance activity and confer ultimate treatment failure.\(^6\)

Although long-term follow-up studies show different and valuable data in different communities as well as long-term safety and treatment outcomes in anti-HCV drug recipients, so far, only a few studies have tracked patients with thalassemia suffering from HCV infection,\(^7,8\) In addition, patients with advanced disease can be at the risk of developing liver disease and HCC even though their viral infection is inactive and may require long-term monitoring of their liver disease.\(^9,10\)

Here, we aimed to report a long-term follow-up of patients with thalassemia, suffering from HCV infection, who underwent DAA antiviral therapy and had identified RASs before baseline treatment initiation.

MATERIALS AND METHODS

Patients and setting

The population of the present cohort study was patients with thalassemia suffering from HCV infection who were admitted for DAA therapy to the referral Firoozgar Hospital, Tehran, Iran affiliated to Iran University of Medical Sciences, from 2016 to 2019. They had related data sheets as patients with thalassemia and relevant data of suffering from chronic HCV infection identified by sophisticated expert hematologists, specialists in infectious diseases, and gastroenterologists. All participants underwent RAS diagnosis based on NS5A and NS5B using polymerase chain reaction (PCR)-sequencing method at the baseline of DAA treatment initiation. Inclusion criteria were having at least an identified RAS based on PCR-sequencing results and published literature, age > 18 years, and signing informed consent. Excluded patients were those who did not refer to the clinic for follow-up and testing, had previous or present co-infection with HBV and/or HIV, in an HCC stage of the disease, have bone marrow defects, underwent liver transplantation, defect creatinine clearance (< 30 mL/min/1.73 m\(^2\)), and history of severe heart disease.

Thalassemia was identified by a hemoglobin electrophoresis test and/or a confirmatory DNA test. Regular deferoxamine injections were received by the participants. HCV infection was identified by viral-specific antibody testing, liver enzymes (AST, ALT, ALK), and viral load calculation using molecular procedures. Transient elastography (FibroScan) was used for liver status evaluation, and > 14.6 kPa was defined as cirrhosis. DAA therapy combination, duration, and dosage were justified as routinely based on cirrhosis and non-cirrhosis conditions evaluated by FibroScan results in which patients with compensated cirrhosis lasts for 6 months and for others 3 months. Treatment follow-up was conducted following a conventional protocol for cirrhotic and non-cirrhotic patients at baseline, end of treatment, and months 6, 12, and 24 after treatment. SVR evaluation was performed based on cirrhosis and non-cirrhosis conditions after the end of treatment at months 6, 12, and 24.

Paraclinical tests and data collection

After 12 hours of fasting, 10 cc whole blood samples were collected in each time from the patients during the follow-up. EDTA containing vacuum tubes (Terumo Europe, Leuven, Belgium) and serum separator tubes (SST, tiger top tube) were used for sample collection. A BS200 auto-analyzer (Mindray, China) was used to measure alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, BUN, alkaline phosphatase (ALP), total and direct bilirubin, albumin, and ferritin. An automated cell counter (Sysmex K-4500,
Sysmex, Japan) was used to assess hemoglobin (Hb), platelet (PLT), and white blood cell count (WBC) as well as complete blood cell count (CBC). Also, other hematological tests, including prothrombin time (PT) and partial thromboplastin time (PTT), were performed. In addition, other demographic data were collected using a questionnaire and medical data repository, including age, sex, and splenectomy and treatment history.

**Molecular tests**

Sera were used for RNA extraction making use of High Pure Viral Nucleic Acid Kit (Roche Diagnostics GmbH, Mannheim, Germany) according to the protocols. A nanodrop spectrophotometer (Thermo Scientific, Wilmington, MA) was used to assess the nucleic acid qualification. Also, a cDNA kit for reverse transcription (RT)-PCR (MBI Fermentas, Toronto, Canada) was utilized for cDNA synthesis. Viral load was quantified using RT-PCR (AmpliCor HCV, Roche) according to the protocols. Additionally, PCR-RFLP or -Sequencing was carried out for HCV genotyping. Moreover, primers for targeting NS5A and NS5B amplification were designed using popular bioinformatics software. Furthermore, PCR was performed using an in-house protocol (not published), and the products were sequenced using ABI 3730xl sequencer after purification by High Pure PCR Product Purification Kit (Roche Diagnostic, Mannheim, Germany). Sequence analysis was performed via CLC Genomics workbench 5 software (CLC bio, Aarhus, Denmark) and aligned against reference sequences including NC_004102 for 1a, EU781825 for 1b, and NC_009824 for 3a subtypes obtained from GeneBank (https://www.ncbi.nlm.nih.gov/).

**RESULTS**

Briefly, out of 91 patients with thalassemia referred to the clinic, 89 passed the inclusion criteria, and 43 underwent RASs investigation using conventional RT-PCR. Overall, nine were identified with baseline RASs, which were used for further follow-up at baseline, at the end of treatment, and months 6, 12, and 24 after treatment (Figure 1).

Data analysis using bioinformatics software showed that there were some identified RASs at baseline, which for subtype 1a included M28V, L31M, and H58P, for subtype
1b: L28M, R30Q, S24F, C316N, and for subtype 3a: C316S, and S24F (Table 1). RAS positive patients’ demographic and laboratory analyses before DAA treatment are shown in Table 1.

Table 2 shows the results of some laboratory tests of nine patients at pre-treatment and immediately at the end of treatment, and also 6 months, 1 year, and 2 years after treatment. The results showed that a significant change occurred in the values of ALT ($p < 0.001$) and AST ($p < 0.001$) levels, where both ALT and AST critically reduced following the treatment.

We also analyzed the results in patients with and without cirrhosis separately. In five patients with cirrhosis, while the ALT ($p = 0.001$) and AST ($p = 0.007$) levels significantly reduced after treatment, the creatinine level slightly increased ($p = 0.025$). More details are reported in Table 3.

Table 4 shows the related results in four non-cirrhotic patients. Based on our results, no significant change was detected in these patients following the treatment.

We also analyzed liver stiffness before and after the treatment and found that in patients with cirrhosis, the means (range) was 25 (12-38) kPa and 14 (10-18) kPa, before and after treatment, respectively. This number was 6 (4-8) kPa both before and after the treatment in patients with cirrhosis.

DISCUSSION

As currently DAAs are widely recommended for HCV infection, baseline-resistant mutants and variants have become a critical issue. Here, we followed up the patients with thalassemia and HCV without a history of DAA and those who relapsed, and those who had DAA RASs prior to the treatment. In this regard, in a cohort of patients with thalassemia, nine cases with baseline RASs were followed up for 2 years after DAA therapy. In a study of 293 patients infected with HCV genotype 3 and with baseline NS5A RASs (Y93H, A30K, L31M), SVR12 rates for sofosbuvir/velpatasvir (SOF/VEL) ± RBV were reported to be 95.9%.$^{11}$ They included 74 (25.3%) patients with cirrhosis, and only one relapse was observed among them, and there were no treatment-related adverse effects. They concluded that NS5A RASs did not have a significant impact on the SVR. Compared with our study results, we have found that NS5A RASs

| HCV subtype | 1a | 1b | 3a | Total |
|-------------|----|----|----|-------|
| Patient No  | 10 | 42 | 6  | 32    | 39   | 9   | 65  | 80  | 46   | 9 cases |
| NS5A RAS    | M28V | M28V, L31M | H58P | H58P | H58P | L31M, R30Q | R30Q | R30Q | S24F | 10 |
| NS5B RAS    | - | - | - | - | - | C316N | C316S | - | 2 |
| Gender (F/M)| M | F | M | F | M | F | F | 5.4 |
| Age (y)     | 34 | 36 | 26 | 34 | 35 | 38 | 25  | 33  | 32.0 ± 4 |
| Hb (g/dl)   | 8.3 | 9.9 | 6.2 | 8.5 | 10.4 | 9.9 | 12.8 | 7.3 | 9.2 | 9.0 ± 1.0 |
| ALT(mg/dL)  | 14 | 154 | 145 | 30 | 72 | 210 | 88  | 13  | 85 ± 69 |
| AST(mg/dL)  | 24 | 145 | 133 | 29 | 58 | 205 | 77  | 29  | 30 | 81 ± 65 |
| Viral load ($<10^5$) (copy/dL) | 82.8 | 19.2 | 195 | 745.3 | 338 | 103 | 28.2 | 217 | 969.7 | 7455 | 360.6 | 23 | 378 | 166.6 | 339 | 279 ± 348 |
| PLT ($<10^5$) mm$^3$ | 763 | 888 | 169 | 925 | 238 | 142 | 723 | 700 | 701 | 510 | 561 ± 310 |
| WBC ($<10^5$) mm$^3$ | 13.8 | 24.9 | 3.9 | 2.3 | 3.85 | 2.4 | 10.5 | 7.45 | 19.6 | 9 ± 7 |
| Thalassemia | Major | Major | Major | Major | Major | Major | Major | Major | Major | Major |
| Treatment failure (IFN/RBV) (Y/N) | Yes | No* | Yes | Yes | No* | Yes | Yes | Yes | Yes | 7.2 |
| Liver stiffness (NC/C) | Cirrhosis | Non-cirrhotic | Cirrhosis | Non-cirrhotic | | | | | 4.5 |

Key: *naïve patient; NC/C: Non-cirrhotic/Cirrhosis; Hb: hemoglobin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; PLT: platelet; WBC: white blood cell count; SD: standard deviation; IFN/RBV: Interferon/Ribavirin; NC/C: Non-cirrhosis/Cirrhosis
do not have adverse outcomes on the results of DAA therapy, and NS5B RASs were not found to have any impact on drug resistance. Additionally, our study showed that there was not any relapse identified associated with genotype, subtype, or RASs, which could prove the DAA safety and efficiency among patients with HCV.

In a cohort of patients with hemoglobinopathies, DAA therapy during 12 weeks of follow-up were

| Table 2: The results of laboratory tests in all patients at pre-treatment and immediately end of treatment, and also 6 months, 1 year, and 2 years after treatment |
| Variables | Pre-treatment | End treatment | 6 months | 12 months | 24 months | p value* |
| WBC ×1000 mm⁻³ | 18.08 ± 22.41 | 16.08 ± 23.80 | 18.45 ± 22.66 | 22.08 ± 24.81 | 22.39 ± 26.61 | 0.097 |
| Hb (g/dl) | 9.06 ± 1.90 | 9.63 ± 1.37 | 9.61 ± 1.01 | 9.49 ± 1.68 | 9.43 ± 1.58 | 0.863 |
| ALT (mg/dL) | 72.00 ± 53.29 | 28.78 ± 19.28 | 30.44 ± 17.57 | 26.67 ± 14.76 | 32.68 ± 20.72 | < 0.001 |
| AST(mg/dL) | 70.56 ± 45.83 | 28.67 ± 8.69 | 30.33 ± 11.95 | 26.11 ± 6.68 | 30.60 ± 6.10 | < 0.001 |
| Cr (mg/dL) | 0.60 ± 0.24 | 0.73 ± 0.16 | 0.81 ± 0.22 | 0.72 ± 0.16 | 0.68 ± 0.13 | 0.061 |
| BUN (mg/dL) | 21.86 ± 6.49 | 23.34 ± 9.99 | 22.11 ± 6.29 | 22.89 ± 7.82 | 22.93 ± 7.26 | 0.963 |
| Ferritin (mg/dL) | 2028.75 ± 1704.90 | 1390.01 ± 1153.60 | 2134.78 ± 1441.86 | 1212.56 ± 1446.39 | 1628.00 ± 1647.66 | 0.773 |
| ALKP (mg/dL) | 238.67 ± 82.61 | 237.00 ± 82.36 | 219.78 ± 83.79 | 212.56 ± 64.66 | 216.32 ± 94.94 | 0.326 |
| Bili-T (mg/dL) | 2.88 ± 1.69 | 2.69 ± 1.08 | 2.66 ± 1.25 | 2.50 ± 1.45 | 3.07 ± 1.24 | 0.693 |
| Bili-D (mg/dL) | 0.59 ± 0.38 | 0.65 ± 0.17 | 0.62 ± 0.24 | 0.60 ± 0.28 | 0.86 ± 0.46 | 0.216 |
| PT (sec) | 14.40 ± 1.80 | 14.34 ± 1.99 | 13.36 ± 1.26 | 14.29 ± 1.47 | 14.53 ± 2.29 | 0.665 |
| PTT (sec) | 40.47 ± 10.54 | 35.43 ± 3.60 | 35.69 ± 3.60 | 35.06 ± 3.89 | 33.88 ± 4.62 | 0.115 |
| Albumin (mg/dL) | 4.49 ± 0.47 | 4.49 ± 0.50 | 4.62 ± 0.30 | 4.36 ± 0.40 | 4.20 ± 0.47 | 0.069 |

Hb: hemoglobin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; PLT: platelet; WBC: white blood cell count; SD: standard deviation; Bili-T: Total Bilirubin; Bili-D: Direct Bilirubin; PT: prothrombin time; PTT: partial thrombin time; Cr: creatinine; WBC: white blood cell

*repeated measure test was utilized

| Table 3: The results of laboratory tests in patients with cirrhosis at pre-treatment and immediately end of treatment, and also 6 months, 1 year and 2 years after treatment |
| Variables | Pre-treatment | End treatment | 6 months | 12 months | 24 months | p value* |
| WBC ×1000 mm⁻³ | 10.35 ± 6.71 | 8.20 ± 5.11 | 10.62 ± 5.56 | 15.62 ± 14.02 | 11.35 ± 6.43 | 0.328 |
| Hb (g/dL) | 9.10 ± 2.38 | 10.02 ± 1.39 | 9.54 ± 0.93 | 10.04 ± 2.12 | 10.24 ± 1.57 | 0.773 |
| ALT(mg/dL) | 77.40 ± 49.67 | 34.80 ± 23.09 | 31.00 ± 17.73 | 26.40 ± 13.87 | 35.42 ± 22.73 | 0.001 |
| AST(mg/dL) | 72.40 ± 46.07 | 28.40 ± 10.21 | 29.40 ± 12.50 | 24.40 ± 8.44 | 32.88 ± 2.68 | 0.007 |
| Cr (mg/dL) | 0.48 ± 0.24 | 0.75 ± 0.20 | 0.78 ± 0.11 | 0.74 ± 0.05 | 0.67 ± 0.08 | 0.025 |
| BUN (mg/dL) | 20.74 ± 8.00 | 18.02 ± 3.73 | 19.20 ± 5.72 | 20.40 ± 7.70 | 19.48 ± 5.67 | 0.922 |
| Ferritin (mg/dL) | 2454.76 ± 2175.91 | 1483.22 ± 1258.91 | 2316.00 ± 1615.66 | 920.00 ± 1149.12 | 1857.20 ± 1646.08 | 0.239 |
| ALKP (mg/dL) | 277.20 ± 92.10 | 265.80 ± 97.68 | 237.20 ± 103.44 | 223.40 ± 68.48 | 254.58 ± 84.3 | 0.245 |
| Bili-T (mg/dL) | 2.68 ± 1.87 | 2.27 ± 0.60 | 2.26 ± 1.08 | 2.10 ± 1.23 | 2.94 ± 0.58 | 0.334 |
| Bili-D (mg/dL) | 0.67 ± 0.49 | 0.72 ± 0.18 | 0.62 ± 0.23 | 0.66 ± 0.38 | 1.10 ± 0.51 | 0.182 |
| PT (sec) | 15.08 ± 2.07 | 14.50 ± 2.29 | 13.60 ± 0.89 | 14.32 ± 0.86 | 13.24 ± 0.83 | 0.446 |
| PTT (sec) | 39.94 ± 7.19 | 36.40 ± 3.97 | 35.64 ± 2.04 | 35.70 ± 3.73 | 33.60 ± 5.32 | 0.411 |
| Albumin (mg/dL) | 4.49 ± 0.47 | 4.49 ± 0.50 | 4.62 ± 0.30 | 4.36 ± 0.40 | 4.20 ± 0.47 | 0.069 |

Hb: hemoglobin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; PLT: platelet; WBC: white blood cell count; SD: standard deviation; Bili-T: Total Bilirubin; Bili-D: Direct Bilirubin; PT: prothrombin time; PTT: partial thrombin time; Cr: creatinine; WBC: white blood cell

*repeated measure test was utilized
evaluated. The results of the study showed that of 139 patients, one did not achieve SVR, and five (3.6%) relapsed. Also, the serum ferritin levels reduction was seen at week 12. The researchers did not report any adverse effects of anti-viral therapy. Although ferritin level showed a fluctuating trend in our follow-up schedule, the overall levels showed a reduction in these patients regardless of genotype, subtype, RASs, and liver injury. This showed a less adverse effect and less possibility of relapse in HCV treatment with DAAs.

In another study on patients with thalassemia major, it was found that the iron level was associated with liver fibrosis but not disease chronicity. Also, another study reported the rate of liver fibrosis progression measured in a four-year follow-up study and found that median iron level was 8.7 mg/dL, and serum ferritin was 1615 g/L, and AST and ALT ratio were 1.5 and 2.5 times upper than the normal range, respectively. Our study showed that the liver stiffness was improved after two years of follow-up and for patients with cirrhosis it reduced drastically from a mean of 25 to 14 kPa (Figure 2). For patients without cirrhosis, no significant differences were found in the liver stiffness before and after the treatment. In other words, DAA therapy in patients with cirrhosis could have positive impacts on virus clearance as well as liver injury and healing of liver lesions.

Moreover, in another study, daclatasvir plus sofosbuvir (DCV + SOF) and daclatasvir plus sofosbuvir plus ribavirin (DCV + SOF + RBV) combination therapies were evaluated, and it was found that 91% of the patients (419/460) obtained SVR12. Only one patient did not achieve SVR and 13 relapsed. SVR12 did not depend on HCV genotype or cirrhosis and liver transplant or HIV/HCV coinfection status. In comparison with our study results, we reported 100% SVR12 for non-cirrhotic and SVR24 for cirrhotic patients, and we did not have any relapse, nor did the patients achieve SVR. This finding showed the efficacy of DAA therapy regardless of the liver injury degree and other host and viral factors.

As DAA therapy achieves stable SVR in a majority of patients regardless of genotype, subtype liver disease status, etc., it could not prevent HCC occurrence or progression. Follow-up studies are recommended for patients surveillance. The present study was an attempt to investigate the treatment outcome of the patients with RASs as a surveillance study, finding that DAA therapy had a satisfactory result on both patients with and without cirrhosis; this is while we followed up patients with

---

Table 4: The results of some laboratory tests in patients without cirrhosis at pre-treatment and immediately end of treatment, and also 6 months, 1 year, and 2 years after treatment

| Variables          | Pre-treatment | End treatment | 6 months | 12 months | 24 months | p value* |
|--------------------|---------------|---------------|----------|-----------|-----------|----------|
| WBC × 1000 mm⁻³   | 27.75 ± 32.48 | 25.94 ± 35.24 | 28.24 ± 33.15 | 30.17 ± 34.97 | 36.19 ± 37.09 | 0.174    |
| Hb (g/dL)          | 9.00 ± 1.42   | 9.15 ± 1.38   | 9.70 ± 1.23 | 8.80 ± 0.60 | 8.42 ± 0.98 | 0.120    |
| ALT (mg/dL)        | 65.25 ± 64.61 | 21.25 ± 12.01 | 29.75 ± 20.07 | 27.00 ± 18.02 | 29.25 ± 20.68 | 0.183    |
| AST (mg/dL)        | 68.25 ± 52.53 | 29.00 ± 7.87  | 31.50 ± 13.00 | 28.25 ± 3.59 | 27.75 ± 8.38 | 0.066    |
| Cr (mg/dL)         | 0.75 ± 0.15   | 0.71 ± 0.14   | 0.84 ± 0.33 | 0.70 ± 0.25 | 0.70 ± 0.19 | 0.441    |
| BUN (mg/dL)        | 23.25 ± 4.72  | 30.00 ± 11.89 | 25.75 ± 5.50 | 26.00 ± 7.79 | 27.25 ± 7.27 | 0.341    |
| Ferritin (mg/dL)   | 1496.25 ± 870.55 | 1273.50 ± 1184.50 | 1908.25 ± 1391.55 | 1578.25 ± 1870.8 | 1341.50 ± 1851.93 | 0.806    |
| ALKP (mg/dL)       | 190.50 ± 36.30 | 201.00 ± 47.51 | 198.00 ± 57.6 | 199.00 ± 66.76 | 168.50 ± 95.26 | 0.798    |
| Bili-T (mg/dL)     | 3.12 ± 1.68   | 3.22 ± 1.40   | 3.15 ± 1.43 | 2.75 ± 1.86 | 3.24 ± 1.89 | 0.800    |
| Bili-D (mg/dL)     | 0.48 ± 0.18   | 0.55 ± 0.10   | 0.63 ± 0.29 | 0.53 ± 0.05 | 0.56 ± 0.1 | 0.692    |
| PT (sec)           | 13.55 ± 1.10  | 14.15 ± 1.88  | 13.05 ± 1.71 | 14.25 ± 2.18 | 16.15 ± 2.62 | 0.205    |
| PTT (sec)          | 41.12 ± 15.05 | 34.22 ± 4.09  | 35.75 ± 5.32 | 34.25 ± 4.50 | 34.22 ± 4.35 | 0.509    |
| Plt × 1000 mm⁻³    | 459.19 ± 406.63 | 736.32 ± 532.1 | 794.25 ± 44.38 | 669.75 ± 2 81.42 | 712.25 ± 351.35 | 0.583    |
| Albumin (mg/dL)    | 4.32 ± 0.39   | 4.35 ± 0.19   | 4.45 ± 0.13 | 4.22 ± 0.26 | 3.92 ± 0.3 | 0.099    |

Hb: hemoglobin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; PLT: platelet; WBC: white blood cell count; SD: standard deviation; Bili-T: Total Bilirubin; Bili-D: Direct Bilirubin; PT: prothrombin time; PTT: partial thrombin time; Cr: creatinine; WBC: white blood cell

*repeated measure test was utilized
different genotypes, subtypes, and RASs frequencies.

Our study has some limitations, such as small sample size and limited population; thus further studies using a larger sample size and longer duration of the follow-up are suggested. Although we had 89 participants, due to strict inclusion criteria and using RASs molecular testing for NS5A and NS5B we had limited population. Iron levels could be another measure to investigate drug efficacy, which we could not take into account, and it is recommended for further studies. However, using regular deferoxamine as an iron-chelating agent could balance its levels as it reflects in ferritin levels, which did not have significant fluctuation during the study period.

Another limitation of our study was just using SVR for patient follow-up, and other measures such as RVR or early viral response (EVR) were not calculated due to considering for fewer interventions and also because of a limited budget.

In conclusion, according to the present follow-up study, no adverse effects of DAA therapy and/or resistance to DAA therapy were found; however, some RASs were observed in these patients. It seems that NS5A and NS5B RASs do have significant impacts on the virus defense against DAAs. Also, DAAs could reduce liver injury as time passes. Additionally, ferritin levels could be adjusted and become lower after HCV treatment in patients with thalassemia.

ACKNOWLEDGMENTS

All authors acknowledge the kind assistance of Blood Transfusion Research Center, High Institute, Transfusion Medicine, Thalassemia Clinic, Tehran, Iran.

Founding support:
This study was done at Iran University of Medical Sciences, Tehran, Iran, and was supported by a project grant coded as 95-04-128-30299.

Ethics declaration:
All ethical issues were done according to the Helsinki declaration. Ethics was approved by the Ethics Committee of Iran University of Medical Sciences, Tehran, Iran by (code IR.IUMS.REC 1396.30299).

ETHICAL APPROVAL
There is nothing to be declared.

CONFLICT OF INTEREST
The authors declare no conflict of interest related to this work.

REFERENCES

1. Le Ngoc C, Thanh TTT, Lan PTT, Mai TN, Hoa TN, My NN, et al. Differential prevalence and geographic distribution of hepatitis C virus genotypes in acute and chronic hepatitis C patients in Vietnam. PloS One 2019;14:e0212734. doi: 10.1371/journal.pone.0212734. eCollection 2019.
2. Zarski JP, David-Tchouda S, Trocmé C, Margier J, Villotitch A, Hilleret MN, et al. Non-invasive fibrosis tests to predict complications in compensated post-hepatitis C cirrhosis. Clin Res Hepatol Gastroenterol 2020;44:524-31. doi: 10.1016/j.clinre.2019.11.005.
3. Omura H, Liu F, Shimakami T, Murai K, Shirasaki T, Kitabayashi J, et al. Establishment and Characterization...
of a New Cell Line Permissive for Hepatitis C Virus Infection. *Sci Rep* 2019;9:7943. doi: 10.1038/s41598-019-44257-5.

4. Bhatia M, Gupta E. Emerging resistance to directly-acting antiviral therapy in treatment of chronic Hepatitis C infection: A brief review of literature. *J Family Med Prim Care* 2020;9:531-8. doi: 10.4103/jfpmc.jfpmc_943_19. eCollection 2020 Feb.

5. Li DK, Chung RT. Overview of direct-acting antiviral drugs and drug resistance of hepatitis C virus. *Methods Mol Biol* 2019;1911:3-32. doi: 10.1007/978-1-4939-8976-8_1.

6. Jones BR, HoweAY, Harrigan PR, Joy JB. The global origins of resistance-associated variants in the non-structural proteins 5A and 5B of the hepatitis C virus. *Virus Evol* 2018;4:vex041. doi: 10.1093/ve/vex041. eCollection 2018 Jan.

7. Zachou K, Arvaniti P, Gatselis NK, Azariadis K, Papadamou G, Rigopoulou E, et al. Patients with haemoglobinopathies and chronic hepatitis C: a real difficult to treat population in 2016? * Mediterr J Hematol Infect Dis* 2017;9:e2017003. doi: 10.4084/MJHID.2017.003. eCollection 2017.

8. Verna EC, Morelli G, Terraut NA, Lok AS, Lim JK, Di Bisceglie AM, et al. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. *J Hepatol* 2020;73:540-8. doi: 10.1016/j.jhep.2020.03.031.

9. Tada T, Toyoda H, Yasuda S, Kumada T, Kurisu A, Ohisa M, et al. Long-term prognosis of liver disease in patients with eradicated chronic hepatitis C virus: an analysis using a Markov chain model. *Hepatol Res* 2020;50:936-46. doi: 10.1111/hepr.13512.

10. Ekpanyapong S, Reddy KR. Hepatitis C virus genotype and viral testing, and on-treatment monitoring: necessary or overkill? *Clin Dilemmas Viral Liv Dis* 2020:41-7. doi: 10.1002/9781119533481.ch7

11. Von Felden J, Vermehren J, Ingliz P, Mauss S, Lutz T, Simon K, et al. High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection. *Aliment Pharmacol Ther* 2018;47:1288-95. doi: 10.1111/apt.14592.

12. Origa R, Ponti ML, Filosa A, Galeota Lanza A, Piga A, Saracco GM, et al. Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies. *Am J Hematol* 2017;92:1349-55. doi: 10.1002/ajh.24911.

13. Lai ME, Origa R, Danjou F, Leoni GB, Vacquer S, Amn F, et al. Natural history of hepatitis C in thalassemia major: a long-term prospective study. *Eur J Haematol* 2013;90:501-7. doi: 10.1111/ejh.12086.

14. Angelucci E, Muretto P, Nicolucci A, Barociani D, Erer B, Gaziev J, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. *Blood* 2002;100:17-21. doi: 10.1182/blood.v100.1.17.